JP2018502077A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502077A5
JP2018502077A5 JP2017532649A JP2017532649A JP2018502077A5 JP 2018502077 A5 JP2018502077 A5 JP 2018502077A5 JP 2017532649 A JP2017532649 A JP 2017532649A JP 2017532649 A JP2017532649 A JP 2017532649A JP 2018502077 A5 JP2018502077 A5 JP 2018502077A5
Authority
JP
Japan
Prior art keywords
compound
formula
ibrutinib
phenoxyphenyl
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017532649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502077A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013424 external-priority patent/WO2016115356A1/en
Publication of JP2018502077A publication Critical patent/JP2018502077A/ja
Publication of JP2018502077A5 publication Critical patent/JP2018502077A5/ja
Pending legal-status Critical Current

Links

JP2017532649A 2015-01-14 2016-01-14 ブルトンチロシンキナーゼ阻害剤の合成 Pending JP2018502077A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
PCT/US2016/013424 WO2016115356A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020171454A Division JP2021035947A (ja) 2015-01-14 2020-10-09 ブルトンチロシンキナーゼ阻害剤の合成

Publications (2)

Publication Number Publication Date
JP2018502077A JP2018502077A (ja) 2018-01-25
JP2018502077A5 true JP2018502077A5 (https=) 2019-02-28

Family

ID=56406389

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017532649A Pending JP2018502077A (ja) 2015-01-14 2016-01-14 ブルトンチロシンキナーゼ阻害剤の合成
JP2020171454A Pending JP2021035947A (ja) 2015-01-14 2020-10-09 ブルトンチロシンキナーゼ阻害剤の合成

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020171454A Pending JP2021035947A (ja) 2015-01-14 2020-10-09 ブルトンチロシンキナーゼ阻害剤の合成

Country Status (16)

Country Link
US (6) US20180009814A1 (https=)
EP (1) EP3245208A4 (https=)
JP (2) JP2018502077A (https=)
KR (1) KR20170102887A (https=)
CN (2) CN113816962A (https=)
AU (2) AU2016206693A1 (https=)
BR (1) BR112017015206B1 (https=)
CA (2) CA3210320A1 (https=)
HK (1) HK1246293A1 (https=)
IL (4) IL308276A (https=)
MA (1) MA41350A (https=)
MX (2) MX366827B (https=)
RU (1) RU2017128308A (https=)
SG (2) SG10201906517VA (https=)
WO (1) WO2016115356A1 (https=)
ZA (1) ZA201704338B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214532B2 (en) * 2015-02-12 2019-02-26 Shanghai Dude Medical Science and Technology Co., Ltd. Process for preparing ibrutinib
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
JP7166331B2 (ja) 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
JP6944496B2 (ja) * 2018-10-22 2021-10-06 ファイザー・インク ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
WO2020095452A1 (ja) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 ジメトキシベンゼン化合物の製造方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
AU2020280904A1 (en) * 2019-05-21 2021-11-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a BTK inhibitor
AU2020278162A1 (en) 2019-05-21 2021-11-18 Janssen Pharmaceutica Nv Processes and intermediates for preparing a BTK inhibitor
WO2022157250A1 (en) 2021-01-21 2022-07-28 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
BRPI0418078A8 (pt) * 2003-12-23 2018-01-02 Astex Therapeutics Ltd composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
IL295053A (en) * 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
CN104507946A (zh) * 2012-07-30 2015-04-08 康塞特医药品有限公司 氘代依鲁替尼
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
US10266535B2 (en) * 2015-01-21 2019-04-23 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Inhibitor of FLT3 kinase and use thereof

Similar Documents

Publication Publication Date Title
JP2018502077A5 (https=)
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
MX2014001669A (es) Compuestos de fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-feni l]-2-alcoxi-2-alquinil/alquenil-etil}-1h-[1,2,4]triazol sustituidos.
JP2016130266A5 (https=)
WO2008121634A3 (en) Nucleoside phosphoramidate prodrugs
EP4328223A3 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物
IN2014MN02175A (https=)
SG10201804791UA (en) 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
JP2011137045A5 (https=)
WO2012044727A3 (en) Manufacturing process for pyrimidine derivatives
WO2019132561A8 (ko) 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
RU2017128308A (ru) Синтез ингибитора тирозинкиназы брутона
MX390748B (es) Composiciones y metodos para tratar accidente cerebrovascular isquemico.
CU24671B1 (es) Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación
WO2010024930A3 (en) Cortistatin analogues and syntheses therof
WO2016141296A8 (en) Tricyclic kinase inhibitors of melk and methods of use
MX2015008543A (es) Proceso para preparar el agente antitumoral 6-(7-((1-aminoaciclopr opil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y su cristalino.
WO2012015681A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
JP2017507175A5 (https=)
CN110891950A (zh) 一种三嗪化合物及其药学上可接受的盐
WO2016038628A3 (en) A process for preparing olodaterol and intermediates thereof
MX2021011775A (es) Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
JP2016535019A5 (https=)